Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: Implications for transfusion safety and HCV infection outcomes

Blood

Volumn 119, Issue 26, 2012, Pages 6326-6334

  Busch, Michael P ^a,b   Murthy, Krishna K ^c   Kleinman, Steven H ^a,d   Hirschkorn, Dale F ^a   Herring, Belinda L ^a   Delwart, Eric L ^a,b   Racanelli, Vito ^e   Yoon, Joo Chun ^e   Rehermann, Barbara ^e   Alter, Harvey J ^f  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BLOOD DONOR; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE TRANSMISSION; DONOR; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION SENSITIVITY; NONHUMAN; PAN TROGLODYTES; PATIENT SAFETY; PLASMA TRANSFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REINFECTION; SEROCONVERSION; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION;

EID: 84863513445     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-393637     Document Type: Article

References (36)

1. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45(6):994-1002. (Pubitemid 40798792)
2. Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion. 2009;49(11):2454-2489.
3. Irving WL, Brown RJP. Acute hepatitis C virus infection: a dynamic-and challenging-concept. J Infect Dis. 2010;202(12):1765-1767.
4. Widell A, Busch M. Exposed or not exposed-that is the question: evidence for resolving and abortive hepatitis C virus infections in blood donors. Transfusion. 2009;49(7):1277-1281.
5. Page-Shafer K, Pappalardo BL, Tobler LH, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol. 2008;46(2):499-506. (Pubitemid 351231293)
6. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216-1226.
7. Mosley JW, Operskalski EA, Tobler LH, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat. 2008;15(2):120-128.
8. Fiebig EW, Heldebrant CM, Smith RI, Conrad AJ, Delwart EL, Busch MP. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr. 2005;39(2):133-137. (Pubitemid 40741109)
9. Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol. 2009;83(7):3288-3297.
10. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45(2):254-264. (Pubitemid 40180144)
11. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/ window period model. Transfusion. 2002;42(8):966-972.
12. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev. 1997;11(3):155-172. (Pubitemid 27358980)
13. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009;119(7):1745-1754.
14. Katayama K, Kumagai J, Komiya Y, et al. Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology. 2004;47(1):57-64. (Pubitemid 38420868)
15. Prince AM, Pawlotsky JM, Soulier A, et al. Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections. J Viral Hepat. 2004;11(3):236-242. (Pubitemid 38658448)
16. Shata MT, Tricoche N, Perkus M, et al. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology. 2003;314(2):601-616. (Pubitemid 37209981)
17. Carroll SS, Ludmerer S, Handt L, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009;53(3):926-934.
18. Chen CM, He Y, Lu L, et al. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother. 2007;51(12):4290-4296. (Pubitemid 350209879)
19. Elmowalid GA, Qiao M, Jeong SH, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A. 2007;104(20):8427-8432. (Pubitemid 47175504)
20. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190-197. (Pubitemid 43214745)
21. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659-662. (Pubitemid 37310924)
22. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436(7053):961-966. (Pubitemid 41191672)
23. Rollier C, Depla E, Drexhage JA, et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol. 2004;78(1):187-196. (Pubitemid 37549731)
24. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197(12):1645-1655. (Pubitemid 36745340)
25. Busch MP, Glynn SA, Wright DJ, et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion. 2005;45(12):1853-1863. (Pubitemid 43971412)
26. Kolk DP, Dockter J, Linnen J, et al. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol. 2002;40(5):1761-1766. (Pubitemid 34493155)
27. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6(5):578-582. (Pubitemid 30305910)
28. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40(1):87-97. (Pubitemid 38868927)
29. Busch MP, Tobler LH, Gerlich WH, Schaefer S, Giachetti C, Smith R. Very low level viremia in HCV infectious unit missed by NAT. Transfusion. 2003;43(8):1173-1174. (Pubitemid 37022381)
30. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev. 2009;23(1):1-12.
31. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acidamplification testing. N Engl J Med. 2004;351(8):760-768.
32. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet. 2002;359(9316):1478-1483. (Pubitemid 34457766)
33. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001;33(2):455-463. (Pubitemid 32119036)
34. Lefrere JJ, Girot R, Lefrere F, et al. Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion. Transfusion. 2004;44(3):343-348. (Pubitemid 38365509)
35. Lawlor E, Power J, Garson J, et al. Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation. Vox Sang. 1999;76(3):138-143. (Pubitemid 29204526)
36. Smith DB, Lawlor E, Power J, et al. A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland. Vox Sang. 1999;76(3):175-180. (Pubitemid 29204533)